Last updated on February 2019

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Brief description of study

The purpose of this Phase 1 study is to evaluate the safety and antitumor activity of Loncastuximab Tesirine (ADCT-402) and Durvalumab in Patients with Advanced Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma.


Detailed Study Description

This is a Phase 1b, open-label, single-arm combination study with a dose escalation phase (Part 1) followed by a dose expansion phase (Part 2). The study will enroll approximately 75 patients.

A standard 3+3 dose escalation design will be used for Part 1. The DLT period will be the 21 days after the first durvalumab dose.

Part 2 will consist of up to 3 expansion cohorts, one for DLBCL, one for MCL, and one for FL. Each cohort will be approximately 20 patients treated at the dose determined in Part 1.

The study will include a Screening Period (of up to 28 days), a Treatment Period (cycles of 3, 6' and 4 weeks), and a Follow-up Period (approximately every 12 week visits for up to 2 years after treatment discontinuation).


Clinical Study Identifier: TX216186

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Baylor Scott & White Medical Center - Temple
Temple, TX United States
  Connect »

Study Coordinator

Rutgers University
New Brunswick, NJ United States
  Connect »

Study Coordinator

University of Colorado Health Memorial Hospital
Colorado Springs, CO United States
  Connect »

Study Coordinator

Sylvester Comprehensive Cancer Center
Miami, FL United States
  Connect »

Study Coordinator

Joe Arrington Cancer Research and Treatment Center
Lubbock, TX United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.